Navigation Links
Circulating tumor cells in blood can predict a patient's response to chemotherapy
Date:12/3/2013

Scientists from Granada have demonstrated, for the first time, that detecting circulating tumour cells (CTCs) in blood and studying the presence of certain genetic markers in them is a technique that allows specialists to predict, with great precision, the response that advanced-cancer patients will have to chemotherapy, as well as the associated secondary effects they may suffer. The key lies in identifying specific proteins in these cells, which make them particularly sensitive to specific drugs.

The scientists, from the Circulating Tumour Cells and Metastasis research group of GENYO (Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Govt.) have received an award at the 9th International Symposium on Minimal Residual Cancer, held recently in Paris, for their study into the use of CTCs and specific markers in these cells, as a clinical tool to determine the response to treatments administered to patients with advanced cancer of the colon.

The patients, studied in the Oncology Unit of the Clinical Hospital of Granada and the Hospital of Motril, underwent a standard treatment in this illness, which includes chemotherapy and a specific monoclonal antibody that reduces the vascularization of the tumour. The study was carried out in collaboration with the Roche Farma laboratory.

The importance of CTCs as the origin of metastasis, which, in turn, is the cause of more than 9 out of every 10 deaths from cancer, has been the subject of work by this group in GENYO for over four years, lead by the University of Granada professors, Jos Antonio Lorente, Mara Jos Serrano and Jos Luis Garca Puche.

GENYO co-operates actively with other Spanish hospitals such as Jan (Dr. Snchez Rovira's team), Crdoba (Dr. Aranda's team) or Almera - Torrecrdenas (with Dr. Juan Torres), as well as carrying out other particularly relevant collaborations with the Dexeus Institute or the Hospital del Mar in Barcelona, along with others in Granada (teams led by Drs. Expsito, Delgado, Czar and Cueto, among others).

Eight Studies

This test on CTCs is one of eight studies the Granada research group is currently carrying out on patients affected by various particularly relevant pathologies in oncology, such as breast cancer, lung cancer, peritoneal carcinomatosis or prostate cancer. These studies have been funded by the Andalusian Regional Government's Health Council, the University of Granada and the pharmaceutical sector.

Due to the importance of this research in applying anti-cancer treatments with greater precision and with fewer side-effects, as well as the importance of CTCs in diagnosing the illness, the work of this GENYO group has caught the attention of the pharmaceutical industry, which habitually collaborates in the carrying out of some of the studies, such as SANOFI, Pangaea, Janssen, Amgen, Ingeniatrix or Roche Farma.


'/>"/>

Contact: José Antonio Lorente
jlorente@ugr.es
34-958-715-500
University of Granada
Source:Eurekalert  

Related medicine news :

1. New research finds flu shot effective regardless of circulating flu strain
2. Sous Vide Circulating Bath Systems Enable Chefs to Achieve Perfect Results
3. Detecting circulating tumor cells
4. New technology allows scientists to capture and preserve cancer cells circulating in the bloodstream
5. Capturing circulating cancer cells could provide insights into how disease spreads
6. Blocking antioxidants in cancer cells reduces tumor growth in mice
7. Why tumors become resistant to chemotherapy?
8. New immunotherapy for malignant brain tumors
9. Study Funded by National Foundation for Cancer Research Reveals Imaging Studies May Predict Tumor Response to Anti-Angiogenic Drugs
10. American Brain Tumor Association-Funded Research Spurs Development of New Treatments
11. Study unveils SINEs potential of re-activating tumor fighting proteins within a cell
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Circulating tumor cells in blood can predict a patient's response to chemotherapy
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, ... relations, content marketing, social media management, corporate communications, SEO and cause marketing, is ... and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding ...
(Date:2/23/2017)... ... 2017 , ... Pink Pig Publishing LLC announces the launch ... the world from different perspectives. By providing a place for people of all ... empathy, and find greater happiness. , "Our approach to structuring content is ...
(Date:2/23/2017)... RI (PRWEB) , ... February 23, 2017 , ... ... today a new partnership with the Rhode Island Consortium for Autism Research and ... an opportunity for children with autism spectrum disorder (ASD) to see films in ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that the ... CM-AT in children aged 3-8 with Autism, is now enrolling at three new sites. ... across the United States. , “There are currently no approved drugs that address ...
(Date:2/22/2017)... Setauket, New York (PRWEB) , ... February 22, ... ... main floor entrance and lobby of a new healthcare contact center in Georgia, ... results. , One of the nation’s largest healthcare systems recently invested $51 million ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... On Wednesday, February 22, 2017, US ... of nine sectors finished the trading sessions in green, four ... Major US indices were also mixed at the close of ... slightly down by 0.09%; the Dow Jones Industrial Average edged ... closed at 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com looks ...
(Date:2/23/2017)... , February 23, 2017 Tillotts ... the Berlin office was opened ... Kritikos . The portfolio includes Entocort ® for ... the treatment of ulcerative colitis, and VistaPrep ® ... the Swiss specialty pharmaceutical company focused on the treatment ...
(Date:2/23/2017)... DIEGO , Feb. 23, 2017 ... a clinical-stage oncology drug development company, announces that ... and Drug Administration (FDA) authorizing the initiation a ... therapeutic treatment for pancreatic cancer. MVT-1075 ( 177 ... radioimmunotherapy (RIT). MabVax plans to initiate the phase ...
Breaking Medicine Technology: